Recombinant Human TACSTD2 protein(Met1-Thr274), His-tagged

• Cat.No.: TACSTD2-3170H
• Product Overview: Recombinant Human TROP2 (NP_002344.2)(Met1-Thr274) was expressed in HEK293, fused with a polyhistidine tag at the C-terminus.

Specification

• Source: HEK293
• Species: Human
• Tag: C-His
• Protein length: Met1-Thr274
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant human TROP2 comprises 259 amino acids and has a predicted molecular mass of 29.4 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh TROP2 is approximately 42-48 kDa due to glycosylation.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 96 % as determined by SDS-PAGE. ≥ 85 % as determined by SEC-HPLC.
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: TACSTD2 tumor-associated calcium signal transducer 2 [ Homo sapiens ]
• Official Symbol: TACSTD2
• Synonyms: TACSTD2; tumor-associated calcium signal transducer 2; M1S1; EGP 1; GA733 1; TROP2; epithelial glycoprotein-1; cell surface glycoprotein TROP2; cell surface glycoprotein Trop-2; pancreatic carcinoma marker protein GA7331; pancreatic carcinoma marker protein GA733-1; gastrointestinal tumor-associated antigen GA7331; membrane component chromosome 1 surface marker 1; membrane component, chromosome 1, surface marker 1; 40kD glycoprotein, identified by monoclonal GA733; EGP1; GP50; EGP-1; GA7331; GA733-1
• Gene ID: 4070
• mRNA Refseq: NM_002353
• Protein Refseq: NP_002344
• MIM: 137290
• UniProt ID: P09758

Reviews

06/05/2020

In addition to its advantages in trials, the manufacturer of the TACSTD2 protein offers exceptional support to researchers.

06/11/2018

Their team of technical experts possess deep knowledge and expertise regarding the protein, ensuring that researchers receive accurate and timely assistance.

01/24/2018

the TACSTD2 protein has been extensively studied and validated in various experimental applications.

Q&As

What diagnostic techniques are used to assess TACSTD2 levels in cancer patients?

Immunohistochemistry and PCR-based assays are common techniques to measure TACSTD2 expression in cancer tissues.

How does TACSTD2 contribute to cancer metastasis?

TACSTD2 promotes cancer cell migration and invasion, leading to metastasis by interacting with various signaling pathways.

Are there clinical trials involving TACSTD2-targeted therapies for cancer treatment?

Yes, there are ongoing clinical trials testing TACSTD2-targeted therapies, including antibody-drug conjugates and immunotherapies.

What are the potential side effects of TACSTD2-targeted therapies?

Common side effects can include fatigue, nausea, diarrhea, and skin rashes, similar to other cancer treatments.

Are there any targeted therapies that focus on TACSTD2?

Yes, monoclonal antibodies and antibody-drug conjugates targeting TACSTD2 are being investigated for cancer treatment.